Literature DB >> 25372673

Anthrax toxin lethal factor domain 3 is highly mobile and responsive to ligand binding.

Kimberly M Maize1, Elbek K Kurbanov1, Teresa De La Mora-Rey1, Todd W Geders1, Dong Jin Hwang1, Michael A Walters1, Rodney L Johnson1, Elizabeth A Amin1, Barry C Finzel1.   

Abstract

The secreted anthrax toxin consists of three components: the protective antigen (PA), edema factor (EF) and lethal factor (LF). LF, a zinc metalloproteinase, compromises the host immune system primarily by targeting mitogen-activated protein kinase kinases in macrophages. Peptide substrates and small-molecule inhibitors bind LF in the space between domains 3 and 4 of the hydrolase. Domain 3 is attached on a hinge to domain 2 via residues Ile300 and Pro385, and can move through an angular arc of greater than 35° in response to the binding of different ligands. Here, multiple LF structures including five new complexes with co-crystallized inhibitors are compared and three frequently populated LF conformational states termed `bioactive', `open' and `tight' are identified. The bioactive position is observed with large substrate peptides and leaves all peptide-recognition subsites open and accessible. The tight state is seen in unliganded and small-molecule complex structures. In this state, domain 3 is clamped over certain substrate subsites, blocking access. The open position appears to be an intermediate state between these extremes and is observed owing to steric constraints imposed by specific bound ligands. The tight conformation may be the lowest-energy conformation among the reported structures, as it is the position observed with no bound ligand, while the open and bioactive conformations are likely to be ligand-induced.

Entities:  

Keywords:  anthrax toxin lethal factor; zinc metallproteinase

Mesh:

Substances:

Year:  2014        PMID: 25372673      PMCID: PMC4220970          DOI: 10.1107/S1399004714018161

Source DB:  PubMed          Journal:  Acta Crystallogr D Biol Crystallogr        ISSN: 0907-4449


  31 in total

1.  Crystal structure of the anthrax lethal factor.

Authors:  A D Pannifer; T Y Wong; R Schwarzenbacher; M Renatus; C Petosa; J Bienkowska; D B Lacy; R J Collier; S Park; S H Leppla; P Hanna; R C Liddington
Journal:  Nature       Date:  2001-11-08       Impact factor: 49.962

2.  The discovery of a potent and selective lethal factor inhibitor for adjunct therapy of anthrax infection.

Authors:  Yusheng Xiong; Judyann Wiltsie; Andrea Woods; Jian Guo; James V Pivnichny; Wei Tang; Alka Bansal; Richard T Cummings; Barry R Cunningham; Arthur M Friedlander; Cameron M Douglas; Scott P Salowe; Dennis M Zaller; Edward M Scolnick; Dennis M Schmatz; Kenneth Bartizal; Jeffrey D Hermes; Malcolm MacCoss; Kevin T Chapman
Journal:  Bioorg Med Chem Lett       Date:  2005-12-09       Impact factor: 2.823

3.  Anthrax lethal factor inhibition.

Authors:  W L Shoop; Y Xiong; J Wiltsie; A Woods; J Guo; J V Pivnichny; T Felcetto; B F Michael; A Bansal; R T Cummings; B R Cunningham; A M Friedlander; C M Douglas; S B Patel; D Wisniewski; G Scapin; S P Salowe; D M Zaller; K T Chapman; E M Scolnick; D M Schmatz; K Bartizal; M MacCoss; J D Hermes
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-23       Impact factor: 11.205

4.  Inhibition of human skin fibroblast collagenase, thermolysin, and Pseudomonas aeruginosa elastase by peptide hydroxamic acids.

Authors:  D Grobelny; L Poncz; R E Galardy
Journal:  Biochemistry       Date:  1992-08-11       Impact factor: 3.162

5.  Identification of small molecule inhibitors of anthrax lethal factor.

Authors:  Rekha G Panchal; Ann R Hermone; Tam Luong Nguyen; Thiang Yian Wong; Robert Schwarzenbacher; James Schmidt; Douglas Lane; Connor McGrath; Benjamin E Turk; James Burnett; M Javad Aman; Stephen Little; Edward A Sausville; Daniel W Zaharevitz; Lewis C Cantley; Robert C Liddington; Rick Gussio; Sina Bavari
Journal:  Nat Struct Mol Biol       Date:  2003-12-29       Impact factor: 15.369

6.  Bacillus anthracis lethal toxin induces TNF-alpha-independent hypoxia-mediated toxicity in mice.

Authors:  Mahtab Moayeri; Diana Haines; Howard A Young; Stephen H Leppla
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

Review 7.  The roles of anthrax toxin in pathogenesis.

Authors:  Mahtab Moayeri; Stephen H Leppla
Journal:  Curr Opin Microbiol       Date:  2004-02       Impact factor: 7.934

Review 8.  Scaling and assessment of data quality.

Authors:  Philip Evans
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2005-12-14

9.  DNASU plasmid and PSI:Biology-Materials repositories: resources to accelerate biological research.

Authors:  Catherine Y Seiler; Jin G Park; Amit Sharma; Preston Hunter; Padmini Surapaneni; Casey Sedillo; James Field; Rhys Algar; Andrea Price; Jason Steel; Andrea Throop; Michael Fiacco; Joshua LaBaer
Journal:  Nucleic Acids Res       Date:  2013-11-12       Impact factor: 16.971

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  4 in total

1.  Identification of a Substrate-selective Exosite within the Metalloproteinase Anthrax Lethal Factor.

Authors:  Allison B Goldberg; Eunice Cho; Chad J Miller; Hua Jane Lou; Benjamin E Turk
Journal:  J Biol Chem       Date:  2016-12-01       Impact factor: 5.157

2.  Ligand-induced expansion of the S1' site in the anthrax toxin lethal factor.

Authors:  Kimberly M Maize; Elbek K Kurbanov; Rodney L Johnson; Elizabeth Ambrose Amin; Barry C Finzel
Journal:  FEBS Lett       Date:  2015-11-11       Impact factor: 4.124

Review 3.  Inhibitors of the Metalloproteinase Anthrax Lethal Factor.

Authors:  Allison B Goldberg; Benjamin E Turk
Journal:  Curr Top Med Chem       Date:  2016       Impact factor: 3.295

4.  Selective function-blocking monoclonal human antibody highlights the important role of membrane type-1 matrix metalloproteinase (MT1-MMP) in metastasis.

Authors:  Albert G Remacle; Piotr Cieplak; Dong Hyun Nam; Sergey A Shiryaev; Xin Ge; Alex Y Strongin
Journal:  Oncotarget       Date:  2017-01-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.